The functions and regulation of the PTEN tumour suppressor: new modes and prospects
- PMID: 29858604
- DOI: 10.1038/s41580-018-0015-0
The functions and regulation of the PTEN tumour suppressor: new modes and prospects
Abstract
PTEN is a potent tumour suppressor, and its loss of function is frequently observed in both heritable and sporadic cancers. PTEN has phosphatase-dependent and phosphatase-independent (scaffold) activities in the cell and governs a variety of biological processes, including maintenance of genomic stability, cell survival, migration, proliferation and metabolism. Even a subtle decrease in PTEN levels and activity results in cancer susceptibility and favours tumour progression. Regulation of PTEN has therefore emerged as a subject of intense research in tumour biology. Recent discoveries, including the existence of distinct PTEN isoforms and the ability of PTEN to form dimers, have brought to light new modes of PTEN function and regulation. These milestone findings have in turn opened new therapeutic avenues for cancer prevention and treatment through restoration of PTEN tumour suppressor activity.
Similar articles
-
The functions and regulation of the PTEN tumour suppressor.Nat Rev Mol Cell Biol. 2012 Apr 4;13(5):283-96. doi: 10.1038/nrm3330. Nat Rev Mol Cell Biol. 2012. PMID: 22473468 Review.
-
PI(3)king apart PTEN's role in cancer.Clin Cancer Res. 2010 Sep 1;16(17):4325-30. doi: 10.1158/1078-0432.CCR-09-2990. Epub 2010 Jul 8. Clin Cancer Res. 2010. PMID: 20622047 Review.
-
Post-translational regulation of PTEN.Oncogene. 2008 Sep 18;27(41):5454-63. doi: 10.1038/onc.2008.242. Oncogene. 2008. PMID: 18794880 Review.
-
Tenets of PTEN tumor suppression.Cell. 2008 May 2;133(3):403-14. doi: 10.1016/j.cell.2008.04.013. Cell. 2008. PMID: 18455982
-
PTEN: a new guardian of the genome.Oncogene. 2008 Sep 18;27(41):5443-53. doi: 10.1038/onc.2008.241. Oncogene. 2008. PMID: 18794879 Review.
Cited by
-
A phase II study of TAS-117 in patients with advanced solid tumors harboring germline PTEN-inactivating mutations.Future Oncol. 2022 Sep;18(30):3377-3387. doi: 10.2217/fon-2022-0305. Epub 2022 Aug 30. Future Oncol. 2022. PMID: 36039910 Free PMC article.
-
Strategy of combining CDK4/6 inhibitors with other therapies and mechanisms of resistance.Int J Clin Exp Pathol. 2024 Jul 15;17(7):189-207. doi: 10.62347/HGNI4903. eCollection 2024. Int J Clin Exp Pathol. 2024. PMID: 39114502 Free PMC article. Review.
-
EPHA3 Contributes to Epigenetic Suppression of PTEN in Radioresistant Head and Neck Cancer.Biomolecules. 2021 Apr 18;11(4):599. doi: 10.3390/biom11040599. Biomolecules. 2021. PMID: 33919657 Free PMC article.
-
The equilibrium of tumor suppression: DUBs as active regulators of PTEN.Exp Mol Med. 2022 Nov;54(11):1814-1821. doi: 10.1038/s12276-022-00887-w. Epub 2022 Nov 16. Exp Mol Med. 2022. PMID: 36385557 Free PMC article. Review.
-
Carbon Nanotube-Mediated Delivery of PTEN Variants: In Vitro Antitumor Activity in Breast Cancer Cells.Molecules. 2024 Jun 11;29(12):2785. doi: 10.3390/molecules29122785. Molecules. 2024. PMID: 38930850 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
